Biomea Fusion (BMEA)
(Delayed Data from NSDQ)
$7.50 USD
-0.06 (-0.79%)
Updated Sep 12, 2024 04:00 PM ET
After-Market: $7.52 +0.02 (0.27%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Brokerage Reports
0 items in cart
Biomea Fusion, Inc. [BMEA]
Reports for Purchase
Showing records 1 - 20 ( 52 total )
Company: Biomea Fusion, Inc.
Industry: Medical - Biomedical and Genetics
2Q24 Results; Awaiting Lift of BMF-219 Clinical Holds; T2D and T1D Phase 2 Data in 4Q24
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Biomea Fusion, Inc.
Industry: Medical - Biomedical and Genetics
Overly Beat Up Ahead of Strong Projected Resurgence; Investment Case Right Now
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Biomea Fusion, Inc.
Industry: Medical - Biomedical and Genetics
Overly Beat Up Ahead of Strong Projected Resurgence; Investment Case Right Now
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Biomea Fusion, Inc.
Industry: Medical - Biomedical and Genetics
Headline Hit for Diabetes; Topline T2D Expansion Phase Data 4Q24; Target Reduced to $15
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Biomea Fusion, Inc.
Industry: Medical - Biomedical and Genetics
Patient Enrollment Wraps Up in COVALENT-111; Topline Data Anticipated in 4Q24
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Biomea Fusion, Inc.
Industry: Medical - Biomedical and Genetics
1Q24 Results; BMF Trials Progressing as Planned; Shaping 219?s Registrational Path With Additional Diabetes Data in 2024
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Biomea Fusion, Inc.
Industry: Medical - Biomedical and Genetics
Initial Proof of Concept Data Show BMF-219 Potential Also in T1D; Building a Case for Upcoming Phase 3 Studies
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Biomea Fusion, Inc.
Industry: Medical - Biomedical and Genetics
200 mg Data Highlight Off-Treatment Sustained Efficacy in T2D; Expansion Phase Ongoing; Initial T1D Data Soon
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Biomea Fusion, Inc.
Industry: Medical - Biomedical and Genetics
Menin Inhibitors Carving Out a Niche in Leukemias: Rationale, Opportunities, and Candidates
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Biomea Fusion, Inc.
Industry: Medical - Biomedical and Genetics
2024 Top Picks: Seeing Important Turnaround Year While Watching the Macro
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Biomea Fusion, Inc.
Industry: Medical - Biomedical and Genetics
2024 Top Picks: Seeing Important Turnaround Year While Watching the Macro
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Biomea Fusion, Inc.
Industry: Medical - Biomedical and Genetics
Covalent Inhibitors Unleashing Their Talents; T2D and T1D Data in 2024; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Biomea Fusion, Inc.
Industry: Medical - Biomedical and Genetics
Phase 2 COVALENT-112 Up and Dosing T1D Patients; Data Anticipated in 2024; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Biomea Fusion, Inc.
Industry: Medical - Biomedical and Genetics
ASH Underscores BMF-219?s Initial Antileukemic Efficacy; Phase 1 COVALENT-101 Progressing As Planned
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Biomea Fusion, Inc.
Industry: Medical - Biomedical and Genetics
Higher Dose COVALENT-111 Results Indicate Enhanced Glycemic Control at Week 26; Additional Long-Term Data in 1Q24
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Biomea Fusion, Inc.
Industry: Medical - Biomedical and Genetics
BMF-219 Completes 22-Week Off-Treatment Marathon; Continued Glycemic Control Keeps Drawing Our Attention
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Biomea Fusion, Inc.
Industry: Medical - Biomedical and Genetics
Critical Near-Term Data Catalysts In Our Universe Represent Thesis Definers
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Biomea Fusion, Inc.
Industry: Medical - Biomedical and Genetics
3Q23 Results; Covalent Inhibitors Set Foot in Diverse Indications; T2D Updates in 4Q23
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Biomea Fusion, Inc.
Industry: Medical - Biomedical and Genetics
BMF-500 Begins Clinical Journey in Acute Leukemia; First Patient Dosed in COVALENT-103 Study
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Biomea Fusion, Inc.
Industry: Medical - Biomedical and Genetics
BMF-219 Stockpiling Diabetes Studies; Launch of Phase 2 COVALENT-112 in T1D Cleared by FDA
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J